Brunswick Exploration Unpacks 302-Metre Lithium Hit as Retail Traders Battle Over ValuationOct 15 Lux Metals Ignites James Bay with 17.57 g/t Gold Intercept Over 19.5 MetresOct 14 Mining Industry Veteran Michael Williams Appointed Executive Chairman of Canadian Uraniumlive
SPONSORED
CannabisHealth Care

Nextleaf Solutions Receives New License From Health Canada

The cannabis extraction company also applies for another patent.

•• 3 Min
Nextleaf Solutions Receives New License From Health Canada

Nextleaf Solutions Ltd. (CSE: OILS), a major cannabis extraction company, announced Thursday that its subsidiary Nextleaf Labs has received a research license from Health Canada and has filed its 12th patent. The research license allows Nextleaf to conduct experiments on humans.

The license is Nextleaf's second license after the standard processing license was granted on September 6, 2019. The research license allows Nextleaf Labs to conduct research and development in the field of analytical testing of cannabis and its derivatives, extraction, refinement and Purification of compounds from cannabis and hemp and the formulation of infused cannabis products as well as performing sensory tests on humans.

Nextleaf receives its 12th patent. The company also announced that it has received a standard patent from the Australian Patent Office for the filtration cell technology it uses to process cannabinoids from cannabis and hemp after extraction. Filtration technology is important because it enables unwanted compounds to be removed from raw cannabis oil extracts in less time, resulting in more efficient throughput rates and a highly desirable, unclean, tasteless, odorless, refined concentrate. We continue to view the macro build for Nextleaf as positive. This is mainly due to two reasons: 1) abundant biomass availability in Canada; 2) Lack of available capital that the breeders can generate themselves. There are abundant amounts of biomass available in Canada.

We highlight two recent harvests: 1) on December 2, 2019, Aleafia announced that it was selling ~ 2,800 kg (its 10,300 kg free range crop) for $ 7.1 million at a price of $ 2.50 per gram to an undisclosed producer that may have been an extractor; 2) In November 2019, WeedMD completed a field crop of more than 20,000 clones on 27 hectares and expects to produce more than eight tons of biomass (8,000 kg) at a cost of ~ $ 0.16 per gram. The total inventory in Canada continues to grow quarter by quarter. To illustrate: In August 2019, inventories increased by 11% to 390,000 kg of unfinished and finished biomass from ~ 350,000 kg in July 2019. The lack of inferior Canadian processing capacity, flawed "vertical integration" and the resulting slow adoption of Cannabis 2.0 could bring the industry short term setbacks.

Recent quarterly announcements from major industry players like Aurora Cannabis and Canopy Growth have suggested major cuts to capital projects. For example, in conjunction with Aurora's FQ1 / 20 results, the company reported two significant capital cuts: 1) to stop construction at its Nordic-2 facility in Denmark to save $ 80 million over the next 12 months, and 2) to decide to "Postpone the majority of final construction and commissioning activities at its Aurora-Sun facility for the foreseeable future" to save ~ $ 110 million in cash. We mainly believe that these cuts are due to poor financial forecasts and strategies. In our opinion, only a small number of licensed growers can fully process their own biomass on a large scale.

As a result, we believe that the execution of Cannabis 2.0 by these big players will be mediocre at best due to the weakness of the cannabis market, lackluster strategy (such as focusing on C02 instead of ethanol-based processing) and shrinking budgets. While this is an overall setback for the industry, we believe these trends could be beneficial for the third party processors who have ramp facilities that can process the biomass on a large scale.

This backs up our thesis that Nextleaf is likely to be on the verge of receiving its first large biomass upgrading and / or whitening labeling contract, provided it can complete its facilities commissioning later this month. Recent weakness not justified We believe that the weakness in Nextleaf's share price over the past few months was due to a wider sector-wide sell correction.

Companies with strong fundamentals were affected, regardless of which segment of the cannabis market they were isolated in. We expect that in the next few months, as retail and consumer interest in Cannabis 2.0 picks up again and negative comments subside, the whole space should benefit. Additionally, extraction-focused companies like MediPharm Labs, Valens and Nextleaf will continue to report strong cash flow quarters and fundamentals will begin to lead the way.

CannabisCanada

More from Cannabis

Most Popular News

  1. SpaceX’s $8B Spectrum Deal Sends AT&T, Verizon, and T-Mobile Plummeting
  2. Is Project Vault Securing America’s Supply Chain or Squeezing It to the Breaking Point?
  3. Why Gautam Lohia Shifted from Global Consulting to Reboot a $20M Tech Micro-Cap
  4. Everyday Luxury, Unstoppable Scale: Aritzia Delivers 44% Net Revenue Growth
  5. Can Navy SEAL Leadership and Big Tech Scale Revolutionize Airborne Threat Detection?

Disclaimer


This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.